A First in Human Double-blind, Randomized Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

Trial Profile

A First in Human Double-blind, Randomized Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs JNJ 64152348 (Primary)
  • Indications Poliomyelitis
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 14 Aug 2017 Planned End Date changed from 18 Apr 2018 to 21 May 2018.
    • 14 Aug 2017 Planned initiation date changed from 14 Sep 2017 to 10 Oct 2017.
    • 08 Mar 2017 Planned End Date changed from 1 Nov 2017 to 18 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top